|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smyth EC, Nilsson M, Grabsch HI, van
Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wei L, Sun J, Zhang N, Zheng Y, Wang X, Lv
L, Liu J, Xu Y, Shen Y and Yang M: Noncoding RNAs in gastric
cancer: Implications for drug resistance. Mol Cancer. 19:622020.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rupaimoole R and Slack FJ: MicroRNA
therapeutics: Towards a new era for the management of cancer and
other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang Q, Zhuang J, Deng Y, Yang L, Cao W,
Chen W, Lin T, Lv X, Yu H, Xue Y and Guo H: miR34a/GOLPH3 axis
abrogates urothelial bladder cancer chemoresistance via reduced
cancer stemness. Theranostics. 7:4777–4790. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Peng Y, Hu S, Zhang K, Wang Y, Rouzi M,
Zhou D and Yang R: Downregulation of microRNA-130a inhibits oral
squamous cell carcinoma proliferation and metastasis via the
hippo-YAP pathway. Cancer Manag Res. 13:4829–4840. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wiggins JF, Ruffino L, Kelnar K, Omotola
M, Patrawala L, Brown D and Bader AG: Development of a lung cancer
therapeutic based on the tumor suppressor microRNA-34. Cancer Res.
70:5923–5930. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu C, Kelnar K, Liu B, Chen X,
Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et
al: The microRNA miR-34a inhibits prostate cancer stem cells and
metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Trang P, Wiggins JF, Daige CL, Cho C,
Omotola M, Brown D, Weidhaas JB, Bader AG and Slack FJ: Systemic
delivery of tumor suppressor microRNA mimics using a neutral lipid
emulsion inhibits lung tumors in mice. Mol Ther. 19:1116–1122.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Feng J, Lu SS, Xiao T, Huang W, Yi H, Zhu
W, Fan S, Feng XP, Li JY, Yu ZZ, et al: ANXA1 binds and stabilizes
EphA2 to promote nasopharyngeal carcinoma growth and metastasis.
Cancer Res. 80:4386–4398. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lu L, Wu M, Lu Y, Zhao Z, Liu T, Fu W and
Li W: MicroRNA-424 regulates cisplatin resistance of gastric cancer
by targeting SMURF1 based on GEO database and primary validation in
human gastric cancer tissues. Onco Targets Ther. 12:7623–7636.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Narayanan S, Cai CY, Assaraf YG, Guo HQ,
Cui Q, Wei L, Huang JJ, Ashby CR Jr and Chen ZS: Targeting the
ubiquitin-proteasome pathway to overcome anti-cancer drug
resistance. Drug Resist Updat. 48:1006632020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xia Q, Li Y, Han D and Dong L: SMURF1, a
promoter of tumor cell progression? Cancer Gene Ther. 28:551–565.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nie J, Liu L, Wu M, Xing G, He S, Yin Y,
Tian C, He F and Zhang L: HECT ubiquitin ligase Smurf1 targets the
tumor suppressor ING2 for ubiquitination and degradation. FEBS
Lett. 584:3005–3012. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fu L, Cui CP, Zhang X and Zhang L: The
functions and regulation of Smurfs in cancers. Semin Cancer Biol.
67:102–116. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xia Q, Zhang H, Zhang P, Li Y, Xu M, Li X,
Li X and Dong L: Oncogenic Smurf1 promotes PTEN wild-type
glioblastoma growth by mediating PTEN ubiquitylation. Oncogene.
39:5902–5915. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Khammanivong A, Gopalakrishnan R and
Dickerson EB: SMURF1 silencing diminishes a CD44-high cancer stem
cell-like population in head and neck squamous cell carcinoma. Mol
Cancer. 13:2602014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rich JT, Neely JG, Paniello RC, Voelker
CC, Nussenbaum B and Wang EW: A practical guide to understanding
Kaplan-Meier curves. Otolaryngol Head Neck Surg. 143:331–336. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Heid CA, Stevens J, Livak KJ and Williams
PM: Real time quantitative PCR. Genome Res. 6:986–894. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo Z, Zhang X, Zhu H, Zhong N, Luo X,
Zhang Y, Tu F, Zhong J, Wang X, He J and Huang L: TELO2 induced
progression of colorectal cancer by binding with RICTOR through
mTORC2. Oncol Rep. 45:523–534. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
An Y, Wang B, Wang X, Dong G, Jia J and
Yang Q: SIRT1 inhibits chemoresistance and cancer stemness of
gastric cancer by initiating an AMPK/FOXO3 positive feedback loop.
Cell Death Dis. 11:1152020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yang W, Ma J, Zhou W, Cao B, Zhou X, Yang
Z, Zhang H, Zhao Q, Fan D and Hong L: Molecular mechanisms and
theranostic potential of miRNAs in drug resistance of gastric
cancer. Expert Opin Ther Targets. 21:1063–1075. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Czabotar PE, Lessene G, Strasser A and
Adams JM: Control of apoptosis by the BCL-2 protein family:
Implications for physiology and therapy. Nat Rev Mol Cell Biol.
15:49–63. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hammond WA, Swaika A and Mody K:
Pharmacologic resistance in colorectal cancer: A review. Ther Adv
Med Oncol. 8:57–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nies AT, Magdy T, Schwab M and Zanger UM:
Role of ABC transporters in fluoropyrimidine-based chemotherapy
response. Adv Cancer Res. 125:217–243. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee SD, Yu D, Lee DY, Shin HS, Jo JH and
Lee YC: Upregulated microRNA-193a-3p is responsible for cisplatin
resistance in CD44(+) gastric cancer cells. Cancer Sci.
110:662–673. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhu C, Huang Q and Zhu H: miR-383
inhibited the cell cycle progression of gastric cancer cells via
targeting cyclin E2. DNA Cell Biol. 38:849–856. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhu M, Zhou X, Du Y, Huang Z, Zhu J, Xu J,
Cheng G, Shu Y, Liu P, Zhu W and Wang T: miR-20a induces cisplatin
resistance of a human gastric cancer cell line via targeting CYLD.
Mol Med Rep. 14:1742–1750. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Du X, Liu B, Luan X, Cui Q and Li L:
miR-30 decreases multidrug resistance in human gastric cancer cells
by modulating cell autophagy. Exp Ther Med. 15:599–605.
2018.PubMed/NCBI
|
|
31
|
Pillai RS, Bhattacharyya SN and Filipowicz
W: Repression of protein synthesis by miRNAs: How many mechanisms?
Trends Cell Biol. 17:118–126. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang H: MicroRNAs and apoptosis in
colorectal cancer. Int J Mol Sci. 21:53532020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Min KH, Yang WM and Lee W: Saturated fatty
acids-induced miR-424-5p aggravates insulin resistance via
targeting insulin receptor in hepatocytes. Biochem Biophys Res
Commun. 503:1587–1593. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cheng D, Zhu C, Liang Y, Xing Y and Shi C:
MiR-424 overexpression protects alveolar epithelial cells from
LPS-induced apoptosis and inflammation by targeting FGF2 via the
NF-kappaB pathway. Life Sci. 242:1172132020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang Y, Lv Z, Fu J, Wang Z, Fan Z and Lei
T: Endogenous microRNA-424 predicts clinical outcome and its
inhibition acts as cancer suppressor in human non-small cell lung
cancer. Biomed Pharmacother. 89:208–214. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu L, Yang F, Lin B, Chen X, Yin S, Zhang
F, Xie H, Zhou L and Zheng S: MicroRNA-424 expression predicts
tumor recurrence in patients with hepatocellular carcinoma
following liver transplantation. Oncol Lett. 15:9126–9132.
2018.PubMed/NCBI
|
|
37
|
Wang ZX, Deng TX and Ma Z: Identification
of a 4-miRNA signature as a potential prognostic biomarker for
pancreatic adenocarcinoma. J Cell Biochem. 120:16416–16426. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao C, Wang XB, Zhang YH, Zhou YM, Yin Q
and Yao WC: MicroRNA-424 inhibits cell migration, invasion and
epithelial-mesenchymal transition in human glioma by targeting
KIF23 and functions as a novel prognostic predictor. Eur Rev Med
Pharmacol Sci. 22:6369–6378. 2018.PubMed/NCBI
|
|
39
|
Xu J, Li Y, Wang F, Cheng B, Ye F, Xie X,
Zhou C and Lu W: Suppressed miR-424 expression via upregulation of
target gene Chk1 contributes to the progression of cervical cancer.
Oncogene. 32:976–987. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhou Y, An Q, Guo RX, Qiao YH, Li LX,
Zhang XY and Zhao XL: miR-424-5p functions as an anti-oncogene in
cervical cancer cell growth by targeting KDM5B via the Notch
signaling pathway. Life Sci. 171:9–15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Bieg D, Sypniewski D, Nowak E and Bednarek
I: MiR-424-3p suppresses galectin-3 expression and sensitizes
ovarian cancer cells to cisplatin. Arch Gynecol Obstet.
299:1077–1087. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Geretto M, Pulliero A, Rosano C, Zhabayeva
D, Bersimbaev R and Izzotti A: Resistance to cancer
chemotherapeutic drugs is determined by pivotal microRNA
regulators. Am J Cancer Res. 7:1350–1371. 2017.PubMed/NCBI
|
|
43
|
Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang
T, Song W, Chen Y, OuYang J, Chen J, et al: miR-424(322) reverses
chemoresistance via T-cell immune response activation by blocking
the PD-L1 immune checkpoint. Nat Commun. 7:114062016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Song MK, Lee JH, Ryoo IG, Lee SH, Ku SK
and Kwak MK: Bardoxolone ameliorates TGF-beta1-associated renal
fibrosis through Nrf2/Smad7 elevation. Free Radic Biol Med.
138:33–42. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Tao Y, Sun C, Zhang T and Song Y: SMURF1
promotes the proliferation, migration and invasion of gastric
cancer cells. Oncol Rep. 38:1806–1814. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Guo J, Xu G, Mao C and Wei R: Low
expression of smurf1 enhances the chemosensitivity of human
colorectal cancer to gemcitabine and cisplatin in patient-derived
xenograft models. Transl Oncol. 13:1008042020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gozani O, Karuman P, Jones DR, Ivanov D,
Cha J, Lugovskoy AA, Baird CL, Zhu H, Field SJ, Lessnick SL, et al:
The PHD finger of the chromatin-associated protein ING2 functions
as a nuclear phosphoinositide receptor. Cell. 114:99–111. 2003.
View Article : Google Scholar : PubMed/NCBI
|
